Evidence map›Paper›PMID 35903346›Full record

ArticleFrontiers in pharmacology2022

Adherence to Statin Therapy and Attainment of LDL Cholesterol Targets in an Outpatient Population of Type 2 Diabetes Patients: Analysis in the DIAbetes and LifEstyle Cohort Twente (DIALECT).

Jelle M Beernink, Milou M Oosterwijk, Job F M van Boven, Hiddo J L Heerspink, Stephan J L Bakker, Gerjan Navis, Roos M Nijboer, Christina M Gant, Heleen Haverkate, Willemien J Kruik-Kollöffel and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Trial
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Jelle M BeerninkDepartment of Internal Medicine/Nephrology, Ziekenhuis Groep Twente, Almelo, Netherlands.
Milou M OosterwijkDepartment of Internal Medicine/Nephrology, Ziekenhuis Groep Twente, Almelo, Netherlands.
Job F M van BovenDepartment of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands.
Hiddo J L HeerspinkDepartment of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands.
Stephan J L BakkerMedication Adherence Expertise Center of the Northern Netherlands (MAECON), Groningen, Netherlands.
Gerjan NavisDivision of Nephrology, Department of Internal Medicine, University of Groningen, University Medical Center Groningen, Groningen, Netherlands.
Roos M NijboerDepartment of Internal Medicine/Nephrology, Ziekenhuis Groep Twente, Almelo, Netherlands.
Christina M GantDivision of Nephrology, Department of Internal Medicine, University of Groningen, University Medical Center Groningen, Groningen, Netherlands.
Heleen HaverkateDepartment of Clinical Pharmacy, Ziekenhuis Groep Twente, Almelo, Netherlands.
Willemien J Kruik-KollöffelDepartment of Clinical Pharmacy, Ziekenhuis Groep Twente, Almelo, Netherlands.
Gozewijn D LavermanDepartment of Internal Medicine/Nephrology, Ziekenhuis Groep Twente, Almelo, Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

cholesteroldiabet mellitus type 2LDL—cholesterolLDL cholesterol targetslipid lowering medicationmedication adherancemedication possesion ratiostatin (HMG-CoA reductase inhibitor)

Identifiers

PMID35903346
PMCPMC9315395

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.